Premal H. Thaker, MD, MS

home / authors / premal-h-thaker-md-ms

Articles

Ongoing Clinical Trials in Locally Advanced Cervical Cancer

Bradley J. Monk, MD, FACOG, FACS;Warner K. Huh, MD, UAB;Bhavana Pothuri, MD;Krishnansu S. Tewari, MD;Premal H. Thaker, MD, MS

November 3rd 2021

Closing out their discussion on locally advanced cervical cancer, panelists discuss ongoing clinical trials and the potential of the involved novel therapies.

Locally Advanced Cervical Cancer: Interpreting the OUTBACK Trial

Bradley J. Monk, MD, FACOG, FACS;Warner K. Huh, MD, UAB;Bhavana Pothuri, MD;Krishnansu S. Tewari, MD;Premal H. Thaker, MD, MS

November 3rd 2021

Considerations for the negative results of the OUTBACK trial, which tested adjuvant chemotherapy in locally advanced cervical cancer.

Locally Advanced Cervical Cancer: Surgery and Standard of Care Therapy

Bradley J. Monk, MD, FACOG, FACS;Warner K. Huh, MD, UAB;Bhavana Pothuri, MD;Krishnansu S. Tewari, MD;Premal H. Thaker, MD, MS

October 27th 2021

Focusing on locally advanced cervical cancer, experts elucidate the role of surgery and standard of care therapy.

What is the Current Role of Biomarker Testing in Cervical Cancer?

Bradley J. Monk, MD, FACOG, FACS;Warner K. Huh, MD, UAB;Bhavana Pothuri, MD;Krishnansu S. Tewari, MD;Premal H. Thaker, MD, MS

October 27th 2021

The panel reflects on the current, optimal use of biomarker testing to guide the management of cervical cancer.

Role of HPV Vaccination and Screening to Prevent Cervical Cancer

Bradley J. Monk, MD, FACOG, FACS;Warner K. Huh, MD, UAB;Bhavana Pothuri, MD;Krishnansu S. Tewari, MD;Premal H. Thaker, MD, MS

October 20th 2021

A comprehensive review of the current paradigm for HPV vaccination and screening to prevent cervical cancer.

Understanding the Biology and Staging of Cervical Cancer

Bradley J. Monk, MD, FACOG, FACS;Warner K. Huh, MD, UAB;Bhavana Pothuri, MD;Krishnansu S. Tewari, MD;Premal H. Thaker, MD, MS

October 20th 2021

Experts provide a brief overview of cervical cancer, focusing on the driving biology and FIGO staging system.

Dr. Thaker on EGEN-001 Combined With Doxorubicin for Ovarian Cancer

Premal H. Thaker, MD, MS

July 28th 2015

Premal H. Thaker, MD, MS, discusses a phase I study examining the combination of EGEN-001 and doxorubicin for the treatment of patients with platinum-resistant ovarian cancer.

<1 2